Search hospitals > Michigan > Wyoming
Gastroenterology Associates of Western Michigan, P.L.C.
Claim this profileWyoming, Michigan 49519
Global Leader in Crohn's Disease
Global Leader in Ulcerative Colitis
Conducts research for Inflammatory Bowel Disease
Conducts research for Ulcer
Conducts research for Gastroparesis
54 reported clinical trials
1 medical researcher
Summary
Gastroenterology Associates of Western Michigan, P.L.C. is a medical facility located in Wyoming, Michigan. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Gastroparesis and other specialties. Gastroenterology Associates of Western Michigan, P.L.C. is involved with conducting 54 clinical trials across 36 conditions. There are 1 research doctors associated with this hospital, such as Allan Coates, MD.Top PIs
Clinical Trials running at Gastroenterology Associates of Western Michigan, P.L.C.
Ulcerative Colitis
Ulcer
Inflammatory Bowel Disease
Non-alcoholic Fatty Liver Disease
Crohn's Disease
Esophagitis
Eosinophilic Esophagitis
Type 2 Diabetes
Nonalcoholic Steatohepatitis
Gastroparesis
Mirikizumab
for Ulcerative Colitis
This trial is testing mirikizumab, a medication for people with severe ulcerative colitis. It aims to see if the drug can reduce gut inflammation by blocking a protein that causes it. The study will last several years. Mirikizumab has shown positive results in early tests for ulcerative colitis.
Recruiting2 awards Phase 31 criteria
Lutikizumab
for Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult subjects with UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of UC. Participants are placed in groups called treatment arms. Each group receives a different treatment. In the Induction Period, participants will be randomized into 1 of 3 arms receiving lutikizumab Dose 1, lutikizumab Dose 2, or adalimumab. In the Maintenance Period, participants who responded to lutikizumab will be randomized into 1 of 2 arms of lutikizumab maintenance and participants who responded to adalimumab will continue to receive adalimumab. All participants who did not achieve clinical response per modified Mayo Score at the end of the Induction period will receive open label lutikizumab. Around 200 adult participants with UC will be enrolled at approximately 280 sites worldwide. In the Induction Period, participants will be randomized to receive intravenous (IV) and subcutaneous (SC) lutikizumab or SC adalimumab for 12 weeks. At the 12 week mark, participants who are on lutikizumab who have responded to treatment will be re-randomized to receive SC lutikizumab at different intervals until Week 52. Participants who are on adalimumab who are responding to treatment will continue to receive adalimumab until Week 52. Participants who do not respond to treatment will receive open-label SC lutikizumab until Week 52. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting0 awards Phase 2
SPH3127
for Ulcerative Colitis
This trial tests a new medication called SPH3127 for people with mild-to-moderate ulcerative colitis. The goal is to see if taking this medication by mouth can safely reduce their symptoms.
Recruiting0 awards Phase 26 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Gastroenterology Associates of Western Michigan, P.L.C.?
Gastroenterology Associates of Western Michigan, P.L.C. is a medical facility located in Wyoming, Michigan. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Gastroparesis and other specialties. Gastroenterology Associates of Western Michigan, P.L.C. is involved with conducting 54 clinical trials across 36 conditions. There are 1 research doctors associated with this hospital, such as Allan Coates, MD.